Search
for
Sort by
Research 30 of 417
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- JAK INHIBITORS IN THE PATHOGENESIS OF ALOPECIA AREATA
- JAK INHIBITORS IN THE PATHOGENESIS OF ALOPECIA AREATA
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- The JAK/STAT signaling pathway: from bench to clinic
- Alopecia areata – Current understanding and management
- Janus Kinase inhibitors in dermatology: a review
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- The Role of Janus Kinase Inhibitors in Dermatology
- The role of janus kinases in the treatment of autoimmune skin diseases
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Under Development JAK Inhibitors for Dermatologic Diseases
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Advances in the mechanism and new therapies of alopecia areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- JAK Inhibitors for Treatment of Alopecia Areata